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In 1881, Hugo Ribbert found the first evidence of cytomegalia and body inclusions in kidney and paratiroid gland cells \[[@CR1]\]. Nevertheless, it was only in 1904, and in parallel with Jesionek and Kiolemenoglu, that the evidence was properly reported \[[@CR1], [@CR2]\]. Years later, between 1956 and 1957 Smith, Rowe and Weller collaborated in the isolation of the virus, known thereafter as "cytomegalovirus" \[[@CR3]--[@CR5]\]. In 1984, 28 years after its first isolation, the first sequence of human cytomegalovirus or HCMV (strain AD169) was published \[[@CR6]\], and only 6 years after, in 1990, the first draft of an annotated HCMV genome was published \[[@CR7]\], at that time the biggest contiguous genome sequenced (GenBank accession number BK000394.5, additional information in Table [1](#Tab1){ref-type="table"}). Since 1990 and until the submission of this original work, 305 full-length *distinct* complete HCMV genomes have been published, including low and high passaged strains, lab-attenuated strains, or artificial genomes (NIAID Virus Pathogen Database and Analysis Resource, ViPR) \[[@CR8]\].

Table 1Full-length HCMV genomes from clinical isolatesGenbankStrainSample originPassage historyLengthOriginIsolation yearSequencing platformEnrichmentReferencesAC146851Towne varS-BACUrine\> 125229,483USA1970SangerUnenriched\[[@CR9]\]AC146904PH-BACBone marrow\< 12229,700USA1984SangerUnenriched\[[@CR9]\]AC146905Toledo-BACUrineHighly-passaged226,889USA1984SangerUnenriched\[[@CR9]\]AC146906TR-BACOcular isolateHighly-passaged234,881USA1994SangerUnenriched\[[@CR9]\]AC146907FIX (VR1814)-BACCervical secretionHighly-passaged229,209Italy1996SangerUnenriched\[[@CR9]\]AC146999AD169 varATCC-BACAdenoidsHighly-passaged233,739USA1956SangerUnenriched\[[@CR9]\]AY315197Towne varS-BACUrineHighly-passaged222,047USA1970SangerUnenriched\[[@CR10]\]AY446894MerlinUrine3235,646UK1999SangerUnenriched\[[@CR11]\]BK000394AD169 varUKAdenoidsHighly-passaged230,290USA1956SangerUnenriched\[[@CR7]\]EF999921TB40-BAC4Throat wash27229,050Germany1999SangerUnenriched\[[@CR12]\]FJ527563AD169 varUCAdenoids\> 50231,781USA1956IlluminaUnenriched\[[@CR13]\]FJ616285Towne varLUrineHighly-passaged235,147USA1970IlluminaUnenriched\[[@CR14]\]GQ221973HAN13Bronchoalveolar lavage3236,219Germany2007Sanger, IlluminaUnenriched\[[@CR15]\]GQ2219743157Urine3235,154UK2001SangerUnenriched\[[@CR15]\]GQ221975JPProstate tissueUnpassaged236,375UK2001SangerUnenriched\[[@CR15]\]GQ396662HAN38Bronchoalveolar lavage2236,112Germany2007IlluminaUnenriched\[[@CR15]\]GQ396663HAN20Bronchoalveolar lavage2235,728UK2007IlluminaUnenriched\[[@CR15]\]GQ4660443301UrineUnpassaged235,703UK2001IlluminaUnenriched\[[@CR15]\]GU179288U8Urine\> 50235,709Italy2003SangerUnenriched\[[@CR16]\]GU179289VR1814Cervical secretion\> 154235,233Italy1996SangerUnenriched\[[@CR16]\]GU179290U11Urine\> 50234,732UK2003SangerUnenriched\[[@CR16]\]GU179291AF1Amniotic fluid\> 50235,937Italy2003SangerUnenriched\[[@CR16]\]GU937742ToledoUrineHighly-passaged235,398USA1984SangerUnenriched\[[@CR11]\]HQ380895JHCBlood4235,476South Korea2003Sanger, 454Unenriched\[[@CR17]\]JN379814U01UrineUnpassaged232,216USA2008Amplicon IlluminaUnenriched\[[@CR18]\]JN379815U04UrineUnpassaged233,910USA2009Amplicon IlluminaUnenriched\[[@CR18]\]JN379816U33UrineUnpassaged232,889USA2009Amplicon IlluminaUnenriched\[[@CR18]\]JX5121976397Urine3235,870UK2001SangerUnenriched\[[@CR14]\]JX512198DavisLiver biopsyHighly-passaged229,768USA1957SangerUnenriched\[[@CR14]\]JX512199HAN1Bronchoalveolar lavage\< 5235,006Germany2007UnknownUnenrichedDavison unpublishedJX512200HAN2Bronchoalveolar lavage3232,940Germany2007UnknownUnenrichedDavison unpublishedJX512201HAN3Bronchoalveolar lavage3235,703Germany2007UnknownUnenrichedDavison unpublishedJX512202HAN8Bronchoalveolar lavage3234,951Germany2007UnknownUnenrichedDavison unpublishedJX512203HAN12Bronchoalveolar lavage3236,006Germany2007UnknownUnenrichedDavison unpublishedJX512204HAN16Urine2235,112Germany2007UnknownUnenrichedDavison unpublishedJX512205HAN19Bronchoalveolar lavage2235,810Germany2007UnknownUnenrichedDavison unpublishedJX512206HAN22Bronchoalveolar lavage2236,379Germany2007UnknownUnenrichedDavison unpublishedJX512207HAN28Bronchoalveolar lavage3236,017Germany2007UnknownUnenrichedDavison unpublishedJX512208HAN31Bronchoalveolar lavage2235,720Germany2007UnknownUnenrichedDavison unpublishedKC519319BE/9/2010Urine2235,631Belgium2010Sanger, 454, IlluminaMultiple displacement amplification\[[@CR19]\]KC519320BE/10/2010Urine2235,215Belgium2010454, IlluminaMultiple displacement amplification\[[@CR19]\]KC519321BE/11/2010Urine2235,061Belgium2010Sanger, 454, IlluminaMultiple displacement amplification\[[@CR19]\]KC519322BE/21/2010UrineUnpassaged235,722Belgium2010Sanger, 454, IlluminaMultiple displacement amplification\[[@CR19]\]KC519323BE/27/2010Urine4234,810Belgium2010454, IlluminaMultiple displacement amplification\[[@CR19]\]KF021605TRVitreousHighly-passaged235,681USA1996SangerUnenriched\[[@CR20]\]KF297339TB40/E clone LisaThroat wash4237,683Germany1999SangerUnenriched\[[@CR21]\]KJ3619462CEN2Bronchoalveolar lavage1235,360Germany2009UnknownUnenrichedWilkie unpublishedKJ3619472CEN5Bronchoalveolar lavage1235,567Germany2009UnknownUnenrichedWilkie unpublishedKJ3619482CEN15Bronchoalveolar lavage1234,949GermanyUnknownUnknownUnenrichedWilkie unpublishedKJ3619492CEN30Bronchoalveolar lavage1236,168GermanyUnknownUnknownUnenrichedWilkie unpublishedKJ361950HAN11Bronchoalveolar lavage3235,276Germany2007UnknownUnenrichedDavison unpublishedKJ361951HAN21Bronchoalveolar lavage3235,834Germany2006UnknownUnenrichedDavison unpublishedKJ361952HAN27Bronchoalveolar lavage2235,861Germany2007UnknownUnenrichedDavison unpublishedKJ361953HAN30Bronchoalveolar lavage2235,483Germany2006UnknownUnenrichedDavison unpublishedKJ361954HAN32Bronchoalveolar lavage2235,458Germany2007UnknownUnenrichedDavison unpublishedKJ361955HAN33Bronchoalveolar lavage3235,512Germany2007UnknownUnenrichedDavison unpublishedKJ361956HAN36Bronchoalveolar lavage2234,844Germany2007UnknownUnenrichedDavison unpublishedKJ361957HAN39Bronchoalveolar lavage1235,056Germany2007UnknownUnenrichedDavison unpublishedKJ361958HAN40Bronchoalveolar lavage2235,763Germany2007UnknownUnenrichedDavison unpublishedKJ361959PAV1Amniotic fluidUnpassaged235,815Italy2005UnknownUnenrichedWilkie unpublishedKJ361960PAV4Amniotic fluidUnpassaged235,272Italy2006UnknownUnenrichedWilkie unpublishedKJ361961PAV5Amniotic fluidUnpassaged235,485Italy2006UnknownUnenrichedWilkie unpublishedKJ361962PAV6Amniotic fluidUnpassaged235,432Italy2007UnknownUnenrichedWilkie unpublishedKJ361963PAV7Amniotic fluidUnpassaged235,142Italy2007UnknownUnenrichedWilkie unpublishedKJ361964PAV8Amniotic fluidUnpassaged235,432Italy2007UnknownUnenrichedWilkie unpublishedKJ361965PAV11Amniotic fluidUnpassaged236,310Italy2007UnknownUnenrichedWilkie unpublishedKJ361966PAV12Amniotic fluidUnpassaged235,616Italy2007UnknownUnenrichedWilkie unpublishedKJ361967PAV23Amniotic fluidUnpassaged235,700Italy2012UnknownUnenrichedWilkie unpublishedKJ361968PAV24Amniotic fluidUnpassaged235,361Italy2012UnknownUnenrichedWilkie unpublishedKJ361969PAV25Amniotic fluidUnpassaged235,902Italy2013UnknownUnenrichedWilkie unpublishedKJ361970PAV26Amniotic fluidUnpassaged236,180Italy2013UnknownUnenrichedWilkie unpublishedKJ361971UKNEQAS1Urine2235,190UK2012UnknownTarget enrichmentWilkie unpublishedKJ426589HANClinical isolateUnknown236,144China2007IlluminaUnenrichedMa unpublishedKJ872539PAV16Amniotic fluidUnpassaged236,240Italy2009IlluminaTarget enrichmentWilkie unpublishedKJ872540PAV18Amniotic fluidUnpassaged234,739Italy2009IlluminaTarget enrichmentWilkie unpublishedKJ872541PAV20Amniotic fluidUnpassaged236,293Italy2013IlluminaTarget enrichmentWilkie unpublishedKJ872542PAV21Amniotic fluidUnpassaged235,901Italy2013IlluminaTarget enrichmentWilkie unpublishedKP745633BE/45/2011Nasopharyngeal aspirate1235,352Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745634BE/32/2010Amniotic fluid1235,205Belgium2010IlluminaMultiple displacement amplification\[[@CR22]\]KP745635BE/5/2012Urine2235,184Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745636BE/7/2011Urine2237,117Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745637BE/9/2011Urine2235,865Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745638BE/15/2010Urine3235,514Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745639BE/10/2011Urine2235,054Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745640BE/22/2010Urine4235,632Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745641BE/31/2011Urine4235,844Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745642CZ/1/2012Urine2235,030Czech Republic2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745643CZ/2/2012Urine2235,226Czech Republic2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745644BE/31/2010Urine4236,028Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745645BE/13/2010Urine3236,032Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745646BE/8/2012Urine3235,889Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745647BE/18/2010Urine5235,871Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745648BE/8/2011Urine2235,111Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745649BE/10/2012Urine2234,754Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745650BE/1/2011Urine3235,833Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745651BE/9/2012Urine2235,836Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745652BE/2/2011Urine4235,810Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745653BE/22/2011Urine2235,612Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745654BE/19/2011Urine2235,446Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745655BE/3/2010Urine2236,597Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745656BE/2/2013Urine3235,156Belgium2013IlluminaMultiple displacement amplification\[[@CR22]\]KP745657BE/13/2011Urine2235,713Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745658BE/14/2012Urine1234,931Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745659BE/3/2011Urine4235,726Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745660BE/6/2011Urine2235,101Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745661BE/33/2010Nasopharyngeal aspirate1235,605Belgium2010IlluminaMultiple displacement amplification\[[@CR22]\]KP745662BE/20/2010Urine4235,516Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745663BE/5/2010Urine2236,345Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745664CZ/2/2013Blood2235,191Czech Republic2013IlluminaMultiple displacement amplification\[[@CR22]\]KP745665BE/16/2012Urine1235,910Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745666BE/7/2012Urine3236,053Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745667BE/5/2011Urine7235,621Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745668BE/18/2011Urine2235,416Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745669BE/28/2011Nasopharyngeal swab2235,732Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745670BE/30/2011Urine2235,350Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745671BE/14/2011Urine9235,498Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745672BE/29/2011Urine2236,364Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745673BE/42/2011Nasopharyngeal aspirate1235,462Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745674BE/33/2011Urine2235,276Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745675BE/23/2011Nasopharyngeal swab2235,425Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745676BE/28/2010Urine4235,974Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745677BE/1/2010Urine2235,705Belgium2010IlluminaMultiple displacement amplification\[[@CR22]\]KP745678BE/25/2010Urine2235,904Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745679BE/24/2010Urine2235,744Belgium2010IlluminaMultiple displacement amplification\[[@CR22]\]KP745680BE/11/2012Urine2235,893Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745681BE/43/2011Nasopharyngeal aspirate1235,100Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745682BE/46/2011Nasopharyngeal aspirate1236,239Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745683BE/12/2011Urine2235,258Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745684BE/11/2011Urine4234,806Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745685CZ/3/2012Urine2234,598Czech Republic2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745686BE/39/2011Nasopharyngeal aspirate1235,982Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745687BE/36/2011Urine2234,373Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745688BE/12/2012Nasopharyngeal swab2235,362Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745689BE/17/2011Urine2235,827Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745690BE/34/2011Urine2235,290Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745691CZ/1/2013Blood2235,139Czech Republic2013IlluminaMultiple displacement amplification\[[@CR22]\]KP745692BE/3/2012Urine2236,051Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745693BE/15/2012Urine1235,508Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745694BE/12/2010Urine8235,195Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745695BE/6/2012Urine5235,164Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745696BE/27/2011Urine5235,392Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745697BE/23/2010Urine4236,066Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745698BE/20/2011Urine2235,272Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745699BE/1/2012Urine2235,150Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745700BE/4/2011Urine2235,808Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745701BE/6/2010Urine2235,329Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745702BE/21/2011Urine5235,849Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745703BE/26/2011Urine2234,902Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745704BE/32/2011Urine2235,633Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745705BE/38/2011Nasopharyngeal swab2235,775Belgium2011IlluminaMultiple Displacement Amplification\[[@CR22]\]KP745706BE/41/2011Bronchoalveolar lavage1235,332Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745707BE/13/2012Urine2235,015Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745708BE/8/2010Urine1235,964Belgium2010IlluminaMultiple displacement amplification\[[@CR22]\]KP745709BE/48/2011Nasopharyngeal aspirate1235,747Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745710BE/2/2012Urine2236,100Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745711BE/24/2011Urine2235,745Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745712BE/19/2010Urine5235,365Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745713BE/35/2011Urine2235,941Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745714BE/29/2010Urine7234,922Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745715BE/44/2011Nasopharyngeal aspirate1235,301Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745716BE/16/2010Nasopharyngeal swab5235,366Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745717BE/2/2010Nasopharyngeal swab2235,138Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745718CZ/1/2011Urine2234,758Czech Republic2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745719BE/26/2010Urine2235,908Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745720BE/15/2011Urine5235,905Belgium2011454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745721BE/14/2010Nasopharyngeal swab2234,537Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745722BE/40/2011Nasopharyngeal aspirate1235,716Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745723BE/37/2011Nasopharyngeal swabs5234,858Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745724BE/4/2012Urine2234,950Belgium2012IlluminaMultiple displacement amplification\[[@CR22]\]KP745725BE/49/2011Nasopharyngeal aspirate1235,317Belgium2011IlluminaMultiple displacement amplification\[[@CR22]\]KP745726BE/30/2010Urine2235,642Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745727BE/17/2010Urine4235,836Belgium2010454, IlluminaMultiple displacement amplification\[[@CR22]\]KP745728BE/4/2010Urine2236,428Belgium2010IlluminaMultiple displacement amplification\[[@CR22]\]KR534196JER847Urine4235,713Israel2009UnknownUnenrichedWilkie unpublishedKR534197JER851Urine4235,435Israel2009UnknownUnenrichedWilkie unpublishedKR534198JER893Bronchoalveolar lavage3235,790Israel2009UnknownUnenrichedWilkie unpublishedKR534199JER1070Amniotic fluidUnpassaged235,492Israel2010UnknownUnenrichedWilkie unpublishedKR534200JER1289kidney biopsy3235,841Israel2002UnknownUnenrichedWilkie unpublishedKR534201JER2002Amniotic fluidUnpassaged235,339Israel2011UnknownUnenrichedWilkie unpublishedKR534202JER2282Amniotic fluidUnpassaged234,549Israel2012UnknownUnenrichedWilkie unpublishedKR534203JER3230Amniotic fluidUnpassaged235,857Israel2011UnknownUnenrichedWilkie unpublishedKR534204JER3855Amniotic fluidUnpassaged234,804Israel2005UnknownUnenrichedWilkie unpublishedKR534205JER4035Amniotic fluidUnpassaged235,314Israel2009UnknownUnenrichedWilkie unpublishedKR534206JER4041Amniotic fluidUnpassaged234,917Israel2005UnknownUnenrichedWilkie unpublishedKR534207JER4053Amniotic fluidUnpassaged235,126Israel2009UnknownUnenrichedWilkie unpublishedKR534208JER4559Amniotic fluidUnpassaged235,673Israel2009UnknownUnenrichedWilkie unpublishedKR534209JER4755Amniotic fluidUnpassaged235,266Israel2012UnknownUnenrichedWilkie unpublishedKR534210JER5268Amniotic fluidUnpassaged235,445Israel2012UnknownUnenrichedWilkie unpublishedKR534211JER5409Amniotic fluidUnpassaged235,943Israel2012UnknownUnenrichedWilkie unpublishedKR534212JER5550Amniotic fluidUnpassaged235,160Israel2012UnknownUnenrichedWilkie unpublishedKR534213JER5695Amniotic fluidUnpassaged235,797Israel2012UnknownUnenrichedWilkie unpublishedKT634296UKNEQAS2Amniotic fluidUnpassaged234,873Australia2013IlluminaTarget enrichmentWilkie unpublishedKT726945NL/Rot6/Nasal/2012Nasal rinse1234,696The Netherlands2012IlluminaTarget enrichment\[[@CR23]\]KT726947UK/Lon1/Blood/2013BloodUnpassaged235,143UK2013IlluminaTarget enrichment\[[@CR23]\]KT726949UK/Lon6/Urine/2011UrineUnpassaged235,199UK2011IlluminaTarget enrichment\[[@CR23]\]KT726950UK/Lon7/Urine/2011UrineUnpassaged235,743UK2011IlluminaTarget enrichment\[[@CR23]\]KT726951UK/Lon8/Urine/2012UrineUnpassaged235,801UK2012IlluminaTarget enrichment\[[@CR23]\]KT959235DBCervical swab3235,512France2009IlluminaTarget enrichment\[[@CR24]\]KU550087NAN1LAAmniotic fluidUnpassaged235,062France2011IlluminaTarget enrichmentWilkie unpublishedKU550088NAN2LAAmniotic fluidUnpassaged234,396France2013IlluminaTarget enrichmentWilkie unpublishedKU550089NAN4LAAmniotic fluidUnpassaged237,120France2013IlluminaTarget enrichmentWilkie unpublishedKU550090NANUUrineUnpassaged235,634France2013IlluminaTarget enrichmentWilkie unpublishedKX544831NRBloodBAC-cloned235,133USA2016454Unenriched\[[@CR25]\]KX544832SUB_24UrineHighly-passaged235,534USA2016454Unenriched\[[@CR25]\]KX544833VR3908UrineHighly-passaged234,711USA2016454Unenriched\[[@CR25]\]KX544834SUB_22UrineHighly-passaged233,965USA2016454Unenriched\[[@CR25]\]KX544835VR5022BloodHighly-passaged234,640USA2016454Unenriched\[[@CR25]\]KX544836VR5201BloodHighly-passaged234,660USA2016454Unenriched\[[@CR25]\]KX544837VR5235BloodHighly-passaged235,666USA2016454Unenriched\[[@CR25]\]KX544838VR7863UrineHighly-passaged234,769USA2016454Unenriched\[[@CR25]\]KX544839TB40-E_UNCThroat swabBAC-cloned228,992USA2016454Unenriched\[[@CR25]\]KX544840UXCA_Merck_UNCUrineBAC-cloned223,782USA2016454Unenriched\[[@CR25]\]KX544841VHL-E_Merck_UNCDuodenal biopsyNA222,309USA2016454Unenriched\[[@CR25]\]KY002201Toledo variantUrineHighly-passaged235,681USA1984IlluminaUnenrichedSuárez unpublishedKY123649HANChild4Bronchoalveolar secretionUnpassaged235,275Germany2012IlluminaTarget enrichment\[[@CR26]\]KY123650HANRTR2BloodUnpassaged235,472Germany2012IlluminaTarget enrichment\[[@CR26]\]KY123651HANRTR4PlasmaUnpassaged235,329Germany2015IlluminaTarget enrichment\[[@CR26]\]KY123652HANRTR5BiopsyUnpassaged235,233Germany2015IlluminaTarget enrichment\[[@CR26]\]KY123653HANSCTR4BloodUnpassaged235,510Germany2011IlluminaTarget enrichment\[[@CR26]\]KY490061PAV31PlasmaUnpassaged235,221ItalyUnknownIlluminaUnenrichedSuárez unpublishedKY490062PAV32PlasmaUnpassaged234,316ItalyUnknownIlluminaTarget enrichmentSuárez unpublishedKY490063PRA1UrineUnpassaged235,826Czech Republic2006IlluminaTarget enrichmentSuárez unpublishedKY490064PRA2UrineUnpassaged234,791Czech Republic2009IlluminaTarget enrichmentSuárez unpublishedKY490065PRA3UrineUnpassaged235,442Czech Republic2009IlluminaTarget enrichmentSuárez unpublishedKY490066PRA4UrineUnpassaged235,513Czech Republic2009IlluminaTarget enrichmentSuárez unpublishedKY490067PRA5UrineUnpassaged234,989Czech Republic2009IlluminaTarget enrichmentSuárez unpublishedKY490068PRA6Amniotic fluidUnpassaged235,717Czech Republic2015IlluminaTarget enrichmentSuárez unpublishedKY490069PRA7UrineUnpassaged236,373Czech Republic2010IlluminaTarget enrichmentSuárez unpublishedKY490070PRA8UrineUnpassaged234,832Czech Republic2012IlluminaTarget enrichmentSuárez unpublishedKY490071HANChild1UrineUnpassaged235,397Germany2013IlluminaTarget enrichmentSuárez unpublishedKY490072HANChild2&3UrineUnpassaged235,913Germany2013IlluminaTarget enrichmentSuárez unpublishedKY490073HANTR1ABloodUnpassaged235,221Germany2012IlluminaTarget enrichmentSuárez unpublishedKY490074HANTR1BBloodUnpassaged235,385Germany2013IlluminaTarget enrichmentSuárez unpublishedKY490075HANTR6Vitreous humorUnpassaged235,930Germany2014IlluminaTarget enrichmentSuárez unpublishedKY490076HANTR8BloodUnpassaged235,791Germany2013IlluminaTarget enrichmentSuárez unpublishedKY490077HANTR9Kidney biopsyUnpassaged235,175Germany2011IlluminaTarget enrichmentSuárez unpublishedKY490078HANTR10BloodUnpassaged234,360Germany2010IlluminaTarget enrichmentSuárez unpublishedKY490079HANSCTR1ABloodUnpassaged235,579Germany2014IlluminaTarget enrichmentSuárez unpublishedKY490080HANSCTR1BStem cell biopsyUnpassaged235,688Germany2014IlluminaTarget enrichmentSuárez unpublishedKY490081HANSCTR2BloodUnpassaged235,843Germany2015IlluminaTarget enrichmentSuárez unpublishedKY490082HANSCTR8BloodUnpassaged235,058Germany2014IlluminaTarget enrichmentSuárez unpublishedKY490083HANSCTR9BloodUnpassaged235,153Germany2016IlluminaTarget enrichmentSuárez unpublishedKY490084HANSCTR10Bronchoalveolar lavageUnpassaged235,018Germany2013IlluminaTarget enrichmentSuárez unpublishedKY490085HANSCTR11ABloodUnpassaged235,632Germany2010IlluminaTarget enrichmentSuárez unpublishedKY490086HANSCTR11BBloodUnpassaged234,962Germany2010IlluminaTarget enrichmentSuárez unpublishedKY490087HANSCTR12BloodUnpassaged235,848Germany2010IlluminaTarget enrichmentSuárez unpublishedKY490088HANSCTR13BloodUnpassaged235,403Germany2011IlluminaTarget enrichmentSuárez unpublishedLT907985TowneUrine\> 125232,608USA1970PacBioUnenriched\[[@CR27], [@CR28]\]MF084223LON1Urine1235,168UK2016IlluminaTarget enrichmentSuárez unpublishedMF084224HER1Urine1235,079Greece2016IlluminaTarget enrichmentSuárez unpublishedX17403AD169Adenoids\> 50229,354USA1956SangerUnenriched\[[@CR7]\]List of all available HCMV genomes derived from clinical isolates extracted from NIAID Virus Pathogen Database and Analysis Resource (ViPR, June 2018) (artificially created mutants have been excluded) \[[@CR8]\]. Different fields describe relevant genome information: GenBank accession number, clinical origin of the sample, passage history, genome length, country of isolation, year of isolation, sequencing method to obtain the genome and the enrichment method that was used, if applicable

Human herpesvirus 5 (HHV-5) or HCMV, a member of the family *Herpesviridae* subfamily *Betaherpesvirinae*, is a human-infecting ubiquitous host--restricted virus with a world-wide seroprevalence between 45 and 100% in adult population \[[@CR29]\]. Primary infections of healthy children and adults are frequently asymptomatic but the virus can establish lifelong persistence as a latent infection, from which it can reactivate and spread new infectious particles \[[@CR30]\]. Latency is characterized by an absence or low-level presence of virus replication and the appearance of viral genomes as circularized episomes inside the nuclei of bone-marrow cells CD33+ and CD34+ and peripheral blood mononuclear cells \[[@CR31]\]. Reactivation of latent forms of the virus, as well as reinfections of the same are common \[[@CR32]\], especially for susceptible groups, as immunocompromised patients, pregnant women, newborns, and elderly. Moreover, in some cases there can be sequelae after infection \[[@CR33]\].

HCMV consists of a linear double-stranded DNA genome with an average longitude of 235 kbp ± 1.9 kbp (see genome size variation at Table [1](#Tab1){ref-type="table"}), one of the largest of all human-infecting viruses. The GC content of HCMV genome (57.5%) is the highest among human *Betaherpesvirinae*, alike the GC content of *Gammaherpesvirinae* (53.8--59.5%) \[[@CR34]\]. The genome is packaged in an icosahedral capsid (*T* = 16) surrounded by a matrix of proteins, the tegument, and enclosed by lipid bilayer, consisting of a mixture between host and virus proteins \[[@CR35]\]. Although the genome is linear inside the nucleocapsid, it is circularized during replication; first through *theta*-like replication and subsequently by rolling circle amplification, generating multiple linked copies in tandem \[[@CR35]\]. Thereafter, the genome is cleaved, linearized and introduced inside the nucleocapsid, following a *headfull* type packaging \[[@CR35]\]. HCMV has a type E genome architecture \[[@CR36]\], therefore composed by 2 big inverted domains: long (L) and short (S). In turn, each domain is composed of a central unique region (U, thus U~L~ and U~S~ respectively) and by two repeated regions, one at the terminal end and the other at the intersection with the other unique domain (thus TR~L~/IR~L~ and TR~S~/IR~S~, respectively), resulting in TR~L~--U~L~--IR~L~--IR~S~--U~S~--TR~S~ as a genome organization (Fig. [1](#Fig1){ref-type="fig"}). Recombination between repetitive regions is possible, changing the orientation of each unique domain, yielding four possible combinations, thereafter referred as genomic isomers \[[@CR37], [@CR38]\] (detailed in Fig. [1](#Fig1){ref-type="fig"}). All four genomic isomers can be found in any infective viral population in equimolar proportion \[[@CR38]\].

Fig. 1Structure and isomerization of HCMV genome. Representation of the HCMV genome (not on scale) with its four possible isomers (panels **a**--**d**). In panel **a**, the orientation of U~L~ and U~S~ is based on U~L~- and U~S~- orientation of the HCMV *wild-type* reference Merlin (GenBank AY446894). Panels **b**--**d** correspond to the other three possible isomer orientations. Genome regions that are characteristic for HCMV: IR~L~, IR~S~, TR~L~, TR~S~, OriLyt repetition (OriLytRep) and a′ are colored in red, purple, gray, green, black and yellow, respectively. Small black arrows correspond to the direction of selected ORFs (UL1, UL145, US1 and US34) which help to illustrate the orientation of the unique regions (big black arrow) between the different isomers. Dashed gray lines connect the specific a′ sequences that contributed to the isomerization

In this review, an overview of HCMV next-generation sequencing (NGS) applications will be given, emphasizing the advances in genomic diversity, strain genotyping, full-length genome methodologies, and coding potential based on transcriptomic and translatomic analysis. In this review, we present the current state-of-the-art and promote future steps in the field.

HCMV variability {#Sec2}
================

"I am very concerned about the use of the same strains, such as Davis or AD169, in different countries and over long periods of time. I wonder how much these could have changed since their initial isolation.---T.H. Weller \[[@CR39]\]."

HCMV has been regarded as being highly variable between isolates. As early as 1960, T.H. Weller already stated that serological differences between cytomegalic inclusion disease (CID) isolates are sufficiently different to differentiate *classes*, thus being an antigenically heterogeneous group \[[@CR5]\]. Later in 1976, Huang and colleagues quantified this variability using DNA--DNA hybridization of 12 different HCMV strains and herpes simplex 1 (HSV-1) and herpes simplex 2 (HSV-2) \[[@CR40]\]. It was found that the similarity at nucleotide level was of at least 80%, when comparing different strains of HCMV, in comparison with the 50% when compared to either HSV-1 or HSV-2 \[[@CR40]\]. Restriction endonuclease typing also supported moderate divergence between different clinical isolates, without any clear grouping or subtyping between isolates, diverging in concurrence of restriction sites, position and size of the digested fragments \[[@CR37], [@CR40]\]. In 1980, Pritchett and colleagues found similar results comparing HCMV AD169 and Towne strains by DNA--DNA hybridization and restriction profiling, implying a similarity of at least 90% at nucleotide level \[[@CR41]\].

In 1990, when first feasible applications of sequencing came available, Chee and colleagues published the first version of HCMV genome (AD169 strain, GenBank X17403, Table [1](#Tab1){ref-type="table"} for related information) \[[@CR7]\], which lead to sequence and genome-wide comparison of different isolates and its coding potential \[[@CR7], [@CR9], [@CR42]\]. Based on comparative genomics and open-reading frame (ORF) analyses, Cha and colleagues in 1996 discovered 19 genes that were missing from high-passage isolates (strains AD169 and Towne) compared to the low-passage Toledo strain and five clinical isolates. As depicted in Fig. [2](#Fig2){ref-type="fig"}, large genomic re-arrangements between AD169 (GenBank AC146999), Towne (GenBank FJ616285) and Toledo (GenBank AC146905) bacterial artificial chromosomes (BACs) can be observed. These re-arrangements, excluding the different possible genome isomers fixed into BACs, are inversions and deletions at the internal end of the U~L~ region, known as the U~L~/b′ sequence, and correspond to missing genes ranging from UL133 to UL154, where several HCMV specific glycoproteins are found in clinical isolates \[[@CR42], [@CR43]\]. Likely, U~L~/b′ is lost by recombination and excision with the terminal a′ sequence during long-term passage of clinical isolates, thus changing the levels of virulence and cell tropism of the viral population \[[@CR42]\]. AD169 and Towne attenuation is thought to have appeared, partially, as consequence of U~L~/b′ deletion \[[@CR43]\]. Later works by Hahn et al. and Bradley et al. described heterogeneous populations of both Towne and AD169 in regards to U~L~/b′ deletion, as well as other mutations \[[@CR13], [@CR44]\]. Hahn et al. provided a method for cloning both the Towne varS (GenBank AC146851) and varL (GenBank FJ616285), short and long Towne variants, into BACs as a mean to produce *genetically stable* viral stocks. Towne varS, as AD169, lacks the U~L~/b′ region, meanwhile Towne varL contains U~L~/b′, resembling an uninverted U~L~/b′ sequence from Toledo and clinical isolates obtained in that period \[[@CR42], [@CR44]\]. A similar phenomenon is also observed in AD169, one of the most extensively passaged HCMV isolates \[[@CR13]\]. In Bradley et al. three AD169 stocks were sequenced: AD169 varUK (GenBank BK000394), AD169 varATCC VR-997 (GenBank AC146999), both derived from NIH 76559 original stock, and AD169 varUC (GenBank FJ527563), using for the first time in HCMV genomics an Illumina sequencing platform. AD169 varATCC proved to be a mixture population of two variants: varS and varL, the later containing U~L~/b′ region, as AD169 varUC. In 2004, Dolan and colleagues sequenced using Sanger method what would become the reference genome for the *wild-type* HCMV, the highly productive Merlin strain (GenBank AY446894), isolated from urine of a congenital infected infant and passaged three times on human foreskin fibroblasts (HFFs) \[[@CR14]\]. In addition, Dolan et al. expanded the comparison between isolates with different passage histories, complementing Cha et al. results \[[@CR42]\], by defining the genomic features of a *wild-type* HCMV, as opposed to high-passage *attenuated* HCMV strains. The Merlin strain has been extensively used as *wild-type* HCMV reference genome, especially as a backbone for genome annotation and annotation transfer. Since the publication of the first HCMV genome and its coding potential, heterogeneity has been studied either through the genotyping of a selected list of genes, viral markers, or through whole-genome comparisons.

Fig. 2Genome structure of classic HCMV strains. Whole-genome alignments of classical HCMV strains (AD169, Merlin, TB40/E, Toledo and Towne) are presented. Linear maps were build using AliTV visualization software \[[@CR45]\], based on whole-genome alignments with Lastz aligner \[[@CR46]\]. Both panels **a, b** depict pair-wise comparisons, expressed as percentage of similarity (green to red), that connect different homologous genomic regions. Genomes are pictured in blue. As shown in the legend, the different type E genome repetitive regions (IR~L~, IR~S~, TR~L~, TR~S~, OriLyt and a′ sequence) are colored. Color pattern is shared with Fig. [1](#Fig1){ref-type="fig"} for comparison purposes. Genome length and repetitive regions are on scale. Length units are expressed in base pairs, as shown in the superior part of both panels. Genomes are ordered by descending genome length. Panel **a** represents the pair-wise genome comparison of AD169, Merlin, TB40/E, Toledo and Towne genomes sequenced from BACs (excluding *wild-type* reference Merlin). GenBank accession numbers, ordered as represented in panel **a**, are AY446894, FJ616285, AC146999, EF999921, and AC146905. Panel **b** illustrates the pair-wise comparison of the same strains from panel **a**, but sequenced using NGS short-read technology (with the exception of Towne). GenBank accession numbers, ordered as represented in panel **b** are F297339, AY446894, FJ616285, GU937742, and FJ527563

Genotyping of viral markers {#Sec3}
===========================

HCMV co-evolved with its human host since diverging from other *Betaherpesvirinae*, circa 120 million years ago \[[@CR47]\], and displays a wide array of molecular strategies that allow for survival and perpetuity. All members of the family *Herpesviridae*, but especially HCMV, have acquired functions that favor persistency, immune evasion and molecular mimicry. Some of those functions have been co-opted from host pre-existing machinery \[[@CR43]\], as well as other viruses \[[@CR11], [@CR48]\] which may account for their considerable genome size. Genes that are linked to persistency, evasion, resistance, or mimicry have been recurrently genotyped in different populations, to assess HCMV variability and its potential thread. These genes of interest, also known as viral markers, can be classified between (i) drug-resistance genes, (ii) virulence, immune evasion, molecular mimicry, and (iii) surface glycoprotein receptors.

Genotyping of HCMV can be distinguished in two approaches: (i) non-PCR and (ii) PCR-based methods. Non-PCR-based methods group direct restriction enzyme digestion \[[@CR37], [@CR40]\] and southern blot \[[@CR41], [@CR42]\]. Both methods were mostly used in the early days to analyze HCMV variability and to generate the first genetic maps \[[@CR49]\]. PCR-based methods group (i) amplicon sequencing and (ii) molecular amplification. Amplicon sequencing has preferentially been conducted with Sanger/dye terminator chemistry sequencing \[[@CR50]--[@CR56]\], whereas variability assessments have been performed using NGS, concretely with second-generation 454 pyrosequencing \[[@CR55], [@CR57], [@CR58]\]. Molecular amplification groups PCR techniques that (i) qualitatively and (ii) quantitatively characterize mutations. Qualitative genotyping was predominantly conducted by RFLPs \[[@CR59], [@CR60]\]. Quantitative or semi-quantitative genotyping has been exclusively conducted by qPCR \[[@CR61], [@CR62]\].

Methods based on restriction enzymes (enzyme digestion, Southern blot, or RFLPs) can fail to detect sequence variability, as only sites sensible to restriction enzymes are analyzed. Conversely, PCR-based methods (including amplicon sequencing) are less prone to miss sequence variability, although only variability found in the amplified region can be studied and poor primer design may reduce the sensibility to detect new variants. Amplicon sequencing has *preferentially* been conducted with Sanger sequencing, as sequencing base accuracy can reach a maximum of 99.999% with this technique \[[@CR63]\]. NGS, specifically second-generation pyrosequencing, has also been used for genotype exploration \[[@CR55], [@CR57]\]. Despite having a lower base accuracy and read length, it can provide more reads, hence more sequencing depth of the sample to call for multiple variants. Under this scenario, NGS platforms are more informative, due to the higher read yield and their increased sensibility to multiple variants. Genotyping of multiple loci from clinical isolates can be scalable by using amplicon NGS. These sequencing platforms can analyze and later reconstruct different sequences, while keeping traceability of sequence origin by using molecular identifiers, or barcodes. Complete gene genotyping should be considered, as genotyping only specific regions of the gene increases the likelihood to lose unknown polymorphic sites \[[@CR64]\] or to overlook new recombining genotypes between different polymorphic sites, as already been described for UL55 (gB) \[[@CR65]\]. Other existing sequencing platforms have yet to be tested on HCMV amplicon genotyping, as sequencing technologies improved fast and full-length genomes where soon available.

Currently, there is no consensus on the classification of HCMV strains based on genotype, evolutionary relationship, or clinical relevance. Loci genotyping should proceed with caution, as the costs of sequencing a full-length HCMV genome have decreased in the last years. Not aiming to sequence a full clinical isolate genome might be an unrepairable opportunity to understand this complex pathogen. Whole-genome sequencing can simultaneously capture all variants and remove the need to design and optimize PCR assays for multiple variant detection, allowing e.g., for a parallel antiviral-resistance testing in a single experiment \[[@CR66]\] or for predicting changes to epitopes for vaccine development \[[@CR67]\].

Next-generation sequencing in HCMV research {#Sec4}
===========================================

"...\[A\] knowledge of sequences could contribute much to our understanding of living matter---F. Sanger \[[@CR68]\]."

Since the apparition of the first massively parallel sequencing technologies in the 2000s, new possibilities for HCMV research emerged after each technological breakthrough. 454 Life Sciences, later known as Roche 454, and Illumina Inc independently created the first massively parallel sequencing platforms, used in the first deep sequencing on HCMV \[[@CR13]\]. These technologies, not only created a new way to recompose full-length HCMV genomes without sequence cloning, but allowed a better understanding of its population variation and coding capacity during infection \[[@CR69]\]. Recently, a new opportunity to differently understand the HCMV genome has appeared with the application of third-generation sequencing, based on long-read real-time sequencing \[[@CR27], [@CR70], [@CR71]\].

Whole-genome sequencing {#Sec5}
-----------------------

Up to the submission of this review, 305 full-length *distinct* HCMV genomes have been published (NIAID Virus Pathogen Database and Analysis Resource, ViPR) \[[@CR8]\], 251 of them derived from clinical isolates (GenBank accession numbers and sequence relevant information can be consulted at Table [1](#Tab1){ref-type="table"}), and of these sequences only 205 correspond to unpassaged or low-passage isolates (\< 4 passages). Since Chee et al. published the first HCMV genome, Sanger sequencing has been regarded as the standard for HCMV drug-resistance detection \[[@CR72]\].

Currently, the most precise full-genome cloning system consists of an embedded complete genome in a BAC with Cre/LoxP self-excising system, amplifying the genome in a bacterial system with very low mutation rates, as the BAC is amplified by the bacterial DNA polymerase. Cre/LoxP self-excising system does not modify the original virus sequence with the exception of a 34 bp insertion downstream of the US28 gene \[[@CR73]\]. Although, BAC cloning can produce long-lasting stable strain amplification systems \[[@CR20], [@CR73]\], cloning and sequencing by *primer walking* can be time-consuming, inefficient and might not be an optimal method for exploring virus diversity within a clinical sample. Interestingly, HCMV genome BAC cloning captures genomes individually, as they are contained inside the viral particles, creating *fixed genetically stable* viral genomes. These stable genomes faithfully represent the individual variants of that viral particle, including its genome isomerization (represented in Fig. [1](#Fig1){ref-type="fig"}), as well as multiple genomic variants, which may not necessarily represent the most abundant form in the viral population or its infective capacity. In Fig. [2](#Fig2){ref-type="fig"}, many genomic re-organizations become apparent when comparing different HCMV strain genomes. In Fig. [2](#Fig2){ref-type="fig"}a, different BAC isolated HCMVs are represented, characterizing inversions spanning the entirety of unique regions when comparing two genomes. These apparent inversions are in fact a result of comparing different HCMV isomered genome sequences, fixed and stabilized in BACs (i.e. TB40/E---BAC vs. Toledo---BAC, in which U~L~ has different directions). In addition, in Fig. [2](#Fig2){ref-type="fig"}a, inversions or translocations that reorganize the classical structure TR~L~--U~L~--IR~L~--IR~S~--U~S~--TR~S~ should be taken with caution, as they may arise from the introduction of the genome into the BAC vector. AD169-BAC (GenBank AC146999) offers a clear example, as its U~S~ region appears to be fragmented and translocated to the terminus of the genome. Once these previous re-organizations are considered, other re-arrangements can be recognized in Fig. [2](#Fig2){ref-type="fig"}. These re-organizations arise from imperfect homologous recombination during HCMV genome replication, being focus of HCMV infective variation studies. Interestingly, these re-organizations can be found in both Fig. [2](#Fig2){ref-type="fig"}a, b, as the same strains are illustrated in both panels but with their genome sequence is derived from either BAC cloning and posterior sequencing or by second-generation sequencing from a pool of viral particles. This comparison between both sequencing methods exemplifies the differences between re-organizations derived from (i) technical procedures (BAC cloning), (ii) viral replication (genome isomers), or by (iii) imperfect homologous recombination and mutation. In this regard, the deletion (and/or inversion) at the U~L~/b′ region, characteristic for high-passage *attenuated* strains, can be observed when comparing AD169, Towne and Toledo strains in both panels of Fig. [2](#Fig2){ref-type="fig"}, as previously discussed in this review.

Despite the benefit of capturing, fixing and genetically stabilize single viral genomes that BAC cloning can offer, most of the partial or full-length genomes have been derived from second-generation sequencing platforms, mainly due to BACs poor scalability for viral population research. These platforms enabled the discovery of different variants in HCMV viral populations (as previously discussed for Towne varS and varL) \[[@CR13]\], and a substantial decrease in time and resources needed for genome sequencing. High-throughput NGS allowed to increase the number of clinical HCMV genomes to more than 170. Sequencing of full-length HCMV genomes was initially performed with Roche 454 pyrosequencing \[[@CR17], [@CR19], [@CR25]\], coupled to either or both Sanger and Illumina sequencing to polish low quality regions, producing 57 HCMV genomes. Illumina sequencing platform rapidly outperformed its competitors with its improved chemistry, yield and base quality, generating most of the available genomes (158 out of 251) \[[@CR15], [@CR20], [@CR22]--[@CR24], [@CR26]\]. Albeit NGS boosted the sequencing of HCMV genomes, direct sequencing of clinical HCMV remained an issue, due to its low viral particle yield of during infection. Common sources of clinical material for HCMV sequencing include: blood, urine, bronchoalveolar liquid, tissue (mostly kidney or liver), and amniotic fluid (a relationship between sequenced genomes and tissue of isolation can be found in Table [1](#Tab1){ref-type="table"}).

Short-read second-generation sequencing provides a solid working approach to the study of single-nucleotide variants (SNVs) due to its high read yield, increased read coverage along the genome and improved sequence error (correction, improving variant detection). Unfortunately, the characterization of genome re-arrangements or structural variants (SVs) with second-generation sequencing can be challenging due to (i) its association with (low-complexity) repetitive regions, (ii) the difficulty of short-reads to span large genomic events, and (iii) to *precisely* localize breakpoint coordinates \[[@CR74]\].

The reconstruction or assembly of a HCMV genome can be a complex task as (i) clinical material has low viral genome copy numbers, directly affecting sequencing coverage and the overall genome quality. Additionally, (ii) HCMV genome contains three regions with low-complexity repetitions at the unique terminal and unique internal end, increasing the difficulty to *correctly* align and recruit reads during genome assembly. Finally, (iii) mixed HCMV populations are expected, either as a result of co-infection of different strains or activation of latent HCMV infections, generating a genetically heterogeneous (or heteroclonal) population \[[@CR55]\]. Discerning which variants co-concur (co-linearize) and belong to the same viral genome may benefit the examination of clonal heterogeneity of the viral population.

Different techniques have been coupled to second-generation sequencing platforms, to increase the yield of viral reads. Most strategies use (i) multiple sequence displacement amplification (MDA) \[[@CR19], [@CR22]\] to increase the input viral DNA in the sample, or (ii) target enrichment to enrich the sample by capturing viral DNA using DNA or RNA probes (also known as *bait libraries*) \[[@CR26], [@CR66], [@CR70], [@CR75]\]. MDA kits use high-fidelity polymerases (generally a ф29 polymerase) in conjunction with a set of random hexamers to amplify DNA at isothermal conditions \[[@CR19], [@CR76], [@CR77]\]. Although, this technique amplifies viral genomic fragments between one to three orders of magnitude \[[@CR19]\], biases have been reported specifically linked to a high allelic drop-out effect (ADO, preferential amplification of a subset of alleles in a heteroallelic sample) and non-uniform amplification of linear double-stranded DNA (related to the GC content of the amplified sequence) \[[@CR19], [@CR76], [@CR78]\]. Both Marine et al. and Roux et al. conducted genome coverage analysis on MDA dsDNA amplified viruses \[[@CR76], [@CR78]\], providing clear evidence that MDA amplification is one of the disturbing factors in completing a full-length genome. A recent study by Borgström and colleagues compared four different MDA available kits during single-cell human DNA amplification: AMPLI1, MALBAC, Repli-G and PicoPlex, taking coverage, SNP calling and ADO to test the reliability of the kits \[[@CR77]\]. Borgström et al. showed that Repli-G produced the most uneven low coverage genome amplification, followed by PicoPlex. AMPLI1 and MALBAC had comparable even coverages \[[@CR77]\]. SNP calling performed poorly by Repli-G kit, only 3% of the variants were detected, in comparison with the 25% detected by MALBAC \[[@CR77]\]. The Repli-G ADO effect is probably linked to the poor performance during SNP calling. Only one allele in all studied loci and replicates was detected \[[@CR77]\]. Target enrichment, conducted mainly with SureSelect^XT^ library enrichment, has been used to obtain over 50 unpassaged HCMV genomes \[[@CR26], [@CR66], [@CR70]\]. By designing custom bait libraries that cover the entire HCMV genome, it is possible to capture (by hybridization and streptavidin bead separation) the fraction of a given NGS library that corresponds to the virus, and further amplify it \[[@CR79]\]. This technique allows to sequence viral genomes *directly* from clinical samples, avoiding virus culturing (used to increase the yield of the virus at cost of virus adaptation to the growing cell line \[[@CR16]\]). SureSelect^XT^ enrichment has been extensively used in the last years \[[@CR23], [@CR26], [@CR66], [@CR70], [@CR80]\]. There are at least two different custom bait libraries being currently used, one developed at the Center for Virus Research, University of Glasgow \[[@CR26]\] and a second designed by the PATHSEEK consortium, jointly with Oxford Gene Technology™ \[[@CR23], [@CR66], [@CR70]\], albeit none of them is publicly available. Both MDA and target enrichment rely on additional PCR amplifications, hence susceptible to introduce a new sequence bias to the sequencing library. Regardless of the increased HCMV sequencing performance that both techniques offer, the omission of infrequent viral variants should be a cause of concern. MDA methods, especially Repli-G, have a known preference to amplify certain regions and variants, leading to uneven low coverage regions and narrowed variant diversity, hence likely over-looking the intrinsic variation in a viral population. Theoretically, a narrowed variant diversity could also be found if target enrichment was used, as its efficiency relies on a library design for *known* but also *unknown* variants.

Assembly of herpesviruses, such as HCMV, can be inaccurate due to its low-complexity repetitive regions as well as its local deviant GC content, producing discontinuities, or gaps, in the assembly \[[@CR15]\]. This inaccuracy is linked to the read length \[[@CR74]\]. A longer read size is more likely to produce reads that can span or bridge regions where the library or sequencing platform might be infra-represented, and correctly characterize repetitious regions, both its boundaries and number of repeats \[[@CR74]\].

Poor connectivity between *distinct* assembled regions, or contigs, is a major challenge for assembling full-length HCMV genomes. As previously stated, assembly inaccuracy can be linked to low-complexity repetitive regions as well as a local deviant GC content \[[@CR74], [@CR81]\], such is the case for type E genomes like HCMV. GC deviant regions may produce read miss-representation in those regions, potentially failing to assemble a full-length genome. Different parts of the sequencing scheme can be responsible for this phenomenon, PCR amplification of the library, cluster amplification, or the reading during sequencing \[[@CR81]\]. However, library amplification by PCR plays the major role in generating GC bias, especially affecting short-read synthesis-based sequencing (i.e., Illumina sequencing platform) \[[@CR81]\]. Likewise, low-complexity repetitive regions can impair an assembly by generating multiple possible positions where reads could align and in that way, generating new sub-alignments, increasing the complexity of the assembly and reducing the accurateness of certain regions \[[@CR74]\]. Poor region connectivity (i.e., an assembly with too many short contigs) can challenge full-length HCMV genome assembly when different viral variants are present in the same sample. Improving this connectivity would increase the recovery of *complete* and *distinct* genomes at sub-strain level, as well as sequencing through repetitive regions \[[@CR74]\]. Consequently, longer reads are desirable, as the longer a given read is, the longer the contigs in the assembly would be, hence increasing the assembly connectivity. Furthermore, improved read-length would likely increase the chance to contain multiple (*distant*) variants in the same read, providing direct evidence of their co-linearity in a given single virus genome from a clonal heterogeneous HCMV population.

Third-generation long-read sequencing platforms, such as SMRT™ from Pacific Biosciences™ and Nanopore sequencing from Oxford Nanopore Technologies™ open the possibility to improve assembly connectivity, providing a promising platform for single virus (partial) genome sequencing, due to its extended read-length. Until the submission of this review, only 3 different long-read HCMV sequencing projects have been published, 2 in 2017: (i) Balázs and colleagues with a hybrid approach using the Pacific Biosciences™, PacBio RS II system and Oxford Nanopore Technologies™, MinION™ platform \[[@CR27], [@CR28], [@CR82]\], and (ii) Eckert et al. with the Oxford Nanopore Technologies™, MinION™ platform \[[@CR70]\]. The last project, published in 2018, by Karamitros and colleagues, also used Oxford Nanopore Technologies™, MinION™ platform \[[@CR71]\]. In Balázs et al., HCMV Towne varS strain (passaged more than 125 times with the 180,887--191,406 region of the original genome substituted with the 1--11,996 region, GenBank LT907985) full-length genome was assembled using cDNA transcripts and the reference Towne (GenBank FJ616285) \[[@CR27], [@CR28]\]. In Eckert et al., HCMV genomes were sequenced, *directly* from clinical material, with and without target enrichment (SureSelect^XT^, without downstream amplification). In contraposition with Balázs et al., only 1.2% of the reads (from non-enriched samples) could be assigned to HCMV; meanwhile for viral enriched samples, 98.7% of the reads were assigned to the virus, reconstructing the HCMV genome up to 99.4% with a mean coverage of 89.9× \[[@CR70]\]. In Karamitros et al., HCMV TB40/E strain (GenBank EF999921) clone Nano, was sequenced using cell-associated replication, without in vitro amplification, and a posterior viral concentration with ultracentrifugation. A 48-h run produced close to 47,000 reads with a uniform average coverage of 100×. The full-length genome was obtained by a co-assembly (or "hybrid de novo assembly", as the authors refer to) of the same filtered reads by a fast long-read assembler, SMARTdenovo \[[@CR83]\], and a short-read assembler, SPAdes \[[@CR84]\]. With this approach Karamitros et al. (raw MinION™ data are available at NCBI---SRA project number PRJEB25285) provide for the first time, using NGS, evidence of viral genome isomers from a type E genome \[[@CR71]\]. Long-read sequencing enabled Karamitros and colleagues to find several SVs in a BAC-derived TB40/E polyclonal sample: (i) a deletion spanning UL144--UL145, (ii) one inversion, (iii) two relocations, and (iii) several short insertions or deletions (deriving in local misalignments) \[[@CR71]\].

Hitherto, no method combines all characteristics to analyze variation in a HCMV polyclonal infection as, or close to, single virus genomes. The ideal method for studying HCMV would have to (i) sequence *directly* from clinical material (no cell or in vitro amplification), (ii) to be *unbiased* (either by enrichment or uneven amplification), and (iii) to provide direct evidence of variant *co-linearity* to an individual viral genome.

Transcription, translation and regulation analysis through RNA-sequencing {#Sec6}
-------------------------------------------------------------------------

Since the publication of the first studies of HCMV transcriptomics by Gatherer and colleagues, the advancements on HCMV RNA-sequencing have highlighted new aspects on its behavior: regulatory small RNAs \[[@CR85], [@CR86]\], new RNA splice variants \[[@CR27], [@CR69]\] and newly detected ORFs \[[@CR69], [@CR87]\]. Early estimates ranged from 164 ORFs \[[@CR14], [@CR69], [@CR88]\] to 220 ORFs \[[@CR89]\], although ribosome profiling identified up to 751 individual ORFs \[[@CR87]\]. Those 751 translationally active ORFs may be a more precise estimate of coding capacity, as it is likely to account for over the (i) 100 splice junctions that HCMV genome contains \[[@CR69], [@CR87]\], (ii) transcript polycistrony (i.e., UL138) \[[@CR90]\] and (iii) short ORFs \[[@CR87]\]. Despite the obvious codifying complexity of HCMV, the *wild-type* reference Merlin (GenBank NC_006273.2) currently has 173 annotated genes, of which 168 are protein-coding genes and 5 non-protein-coding genes.

According to Gatherer et al. (BioProject PRJEB2543, see Table [2](#Tab2){ref-type="table"} for additional project information) 3 different types of transcripts can be expected when analyzing HCMV infections: (i) protein-coding transcripts, (ii) non-coding non-overlapping transcripts (RNA2.7, RNA5.0, and RNA1.2 long non-coding RNA or lncRNA), and (iii) antisense transcripts (transcribed antisense with respect to protein-coding regions) \[[@CR69], [@CR85]\]. Studying the infectious behavior of HCMV Merlin strain in HFFs at 72 h post infection showed that the presence of antisense transcripts throughout the HCMV genome, by strand-specific RNA-seq (in \[[@CR69]\] referred as "directional sequencing or DDS") and strand-unspecific RNA-seq (in \[[@CR69]\] referred as "non-directional transcript sequencing NDS"), represented a 8.7% of the overall transcription \[[@CR69]\]. In addition, RNA2.7, RNA5.0, and RNA1.2 transcripts account for 65.1% of the overall transcription, especially RNA2.7 that represents the 46.8% of the overall transcription. Strikingly, protein-coding transcripts only account for a third of the overall transcript production \[[@CR69]\]. New splicing sites were discovered, leading to the description of new alternative splicing events and confirmation of four novel gene transcripts (RL8A, RL9A, UL150, and US33A) \[[@CR69]\]. A year later, Stern-Ginossar and colleagues (BioProject PRJNA177721) used ribosome profiling (sequencing of mRNA protected within the ribosomes) to study Merlin transcription in HFFs at 5, 24, and 72 h post infection \[[@CR87]\]. 751 translated ORFs were found with only 147 being previously described. These novel putative ORFs where derived from (i) nested ORFs (in and out of frame), (ii) upstream short ORFs, (iii) antisense ORFs, and (iv) short unpredicted ORFs (ORFs coding for protein between 100 and 200 aminoacids \[[@CR91]\]). Multiple ORFs were translated from RNA1.2, RNA2.7 and RNA4.9 lncRNA, acting as a precursor polycistronic mRNA \[[@CR87]\].

Table 2HCMV RNA-sequencing projectsBioProject numberStudy nameHCMV strainHost cell lineTemporal dataSequencing platformLibrary sourceSample numberReferencesPRJNA421010miRNA-mediated targeting of human cytomegalovirus reveals biological host and viral targets of IE2TB40/EMCR-5 and THP-11--10 daysIlluminacDNA16\[[@CR92]\]PRJEB25680Dual-platform long-read RNA-sequencing of the human cytomegalovirus lytic transcriptomeTowne varSMCR-51, 3, 6, 12, 24, 72, 96 and 120 hOxford Nanopore TechnologiescDNA12\[[@CR82]\]PRJEB22072Transcriptome analysis of the human cytomegalovirus using pacific biosciences RSII platformTowne varSMCR-51, 3, 6, 12, 24, 72, 96 and 120 hPacific BiosciencescDNA, oligo-dT, random PCR26\[[@CR27], [@CR28]\]PRJNA389726Transcriptome-wide characterization of human cytomegalovirus in natural infection and experimental latencyTB40/E, ∆*UL135*, ∆*UL138* and 12 latent clinical isolatesCD34+, PBMC2 and 6 daysIlluminacDNA39\[[@CR93]\]PRJNA388483Cellular responses to human cytomegalovirus infectionTB40/EMRC-5 and ARPE-1924, 72 and 120 hIlluminacDNA12\[[@CR94]\]PRJNA373848Transcriptome analysis of HCMV infected tissuesTB40/EARPE-19 and decidual tissue1 or 7 daysIlluminacDNA4\[[@CR95]\]PRJEB15199HCMV transcriptome in primary monocyte-derived cell typesTB40/EPBMC72 hIlluminaOligo-dT33\[[@CR96]\]PRJNA342503RNA binding protein CPEB1 remodels host and viral RNA landscapes \[RNA-Seq\]TB40/E, TowneHUES9, H9 and HFFs48 and 96 hIlluminacDNA6\[[@CR97]\]PRJNA304028microRNA expression analysis of CMV infected human fibroblasts in two culturesAD169HELF-977 and\
HAF-16080 and 3 hIlluminacDNA, size fractionation2\[[@CR98]\]PRJNA299678Transcriptome analysis of diverse cell types infected with human cytomegalovirus \[RNA-Seq\]TB40E and TowneHFF, EC and NPC2 and 8 hIlluminacDNA22\[[@CR97]\]PRJNA269099MicroRNA targetome analysis during HCMV infectionTowne varLHFF0, 24, 48 and 72 hIlluminacDNA, size fractionation40\[[@CR99]\]PRJNA177721Decoding human cytomegalovirus using ribosome profilingMerlinHFF5, 24 and 72 hIlluminacDNA16\[[@CR87]\]PRJNA148583High-resolution profiling and analysis of viral and host small RNAs during human cytomegalovirus infectionTowneHFF24 and 72 hIlluminacDNA, size fractionation2\[[@CR85]\]PRJEB2543High-resolution human cytomegalovirus transcriptomeMerlinHFF24 hIlluminacDNA2\[[@CR69]\]PRJNA340198Gene expression of human THP-1 cells infected by cytomegalovirusTowneTHP-14 daysSangercDNA3\[[@CR100]\]PRJNA257463Ribosome profiling reveals pervasive translation outside of annotated protein-coding genesUnknownUnknownUnknownIlluminacDNA4\[[@CR101]\]PRJNA394123Defining the transcriptional landscape during cytomegalovirus latency with single-cell RNA-sequencingTB40EHPC3, 4, 5, 6, 7 and 14 hIlluminacDNA7\[[@CR102]\]Relation of all available HCMV expression and translation projects using RNA-seq data extracted from (NCBI, July 2018). Relevant information is attributed to each experiment by its BioProject number, which can be used as unique entry point to access the raw data produced in the RNA-seq experiment. Each RNA-seq experiment is linked to the type of library, sequencing platform, number of samples run in the experiment, as well as the name and basic conditions of study (HCMV strain, cell line and time of infection that was analyzed)

MicroRNAs (miRNAs) are small RNAs of 22 nucleotides long, transcribed by RNA polymerase II \[[@CR92]\], related to RNA silencing and post-transcriptional regulation of gene expression. Both functions have been studied for their possible regulatory role during an HCMV infection \[[@CR10], [@CR85], [@CR103]\]. While miRNAs are known to be non-immunogenic, some are known to have a regulatory function in viruses \[[@CR86]\]. HCMV is known to produced mature miRNAs during infection \[[@CR10], [@CR103]\]. Stark and colleagues (BioProject PRJNA148583) studied host (HFFs) and HCMV Towne miRNAs profiles at 24 and 72 h post infection. Up to 20% of the miRNAs were from viral origin, providing evidence of 22 miRNAs being incorporated into the endogenous host silencing machinery \[[@CR85]\]. In contrast, Meshesha and colleagues described the fraction of miRNA dropped to only 5% \[[@CR86]\]. Even if Stark et al. and Meshesha et al. identified the same seven top most abundant transcripts (miR US5-2-3p, US25-1-5p, US25-2-3p, US25-2-5p, UL22A-3p, UL22A-5p, and UL36-5p), their abundances substantially differed. Those changes in abundance could be attributed to 3 different causes: firstly, (i) two different HCMV strains were used (Towne in Stark et al. vs. AD169 and 3 clinical isolates in Meshesha et al.). Secondly, (ii*)* RNA was collected at different time points (72 h vs. 96 h post infection), and finally (iii) different methods of miRNA assignment were used (mapping reads with Bowtie v0.12 to miRBase v16.0 vs. mapping reads with BWA v0.5 miRBase v17.0) \[[@CR85], [@CR86]\]. Using previously published ribosome profiling data by Stern-Ginossar et al., Ingolia and colleagues (BioProject PRJNA257463) found evidence of novel polypeptide production in RNA2.7 transcript, capable to induce immune responses from the host \[[@CR101]\]. Kim et al. (BioProject PRJNA269099) found that a large fraction of human miRNAs targets was shared with viral miRNAs in HFFs infected with Towne varL after 24, 48 and 72 h post infection \[[@CR99]\]. In 2016, Buzdin and colleagues (BioProject PRJNA304028) could link a complete suppression of host miRNAs regulation during early stages (3 h) of an HCMV infection, by infecting embryonic lung fibroblasts (HELF-977) and skin fibroblasts (HAF-1608) with AD169 \[[@CR98]\]. Lastly, Stark et al. found evidence of miRNAs being derived from the lncRNA RNA2.7, contributing to profile HCMV long RNAs as precursors to other functional RNAs. Interestingly, Stern-Ginossar et al. found similar results applying ribosome profiling techniques, describing lncRNAs as precursors for putative short proteins \[[@CR87]\].

Transcriptomics can also be used to understand the processes of cell tropism and infection in different cell types. Van Damme et al. (BioProject PRJEB15199) compared differences in expression between TB40/E infected macrophages and dendritic cells (DCs) derived from whole blood donations \[[@CR96]\]. Interestingly, in primary cell types, differentially expressed genes often belong to clusters, suggesting a functional coordination between those transcripts coming from genes of the same family. Concretely, the decrease in expression of RL11--RL13--RL14--UL1 and UL4--UL11; and the increase of UL120--UL121, UL148D--UL149, and US33--US34A in DCs were strikingly pronounced \[[@CR96]\]. In macrophages type 1, the cluster UL81--UL86 appeared to have its expression generally decreased (although UL81--UL82 and UL85 did not reach clear significance). Contrary, in macrophages type 2, the same cluster, UL82--UL86 had its expression increased (UL84 was not significant), as well as RL11--RL12, UL2-3, and UL148A--UL149 loci. Similarly, the unique short region US7--US9 had their expression increased \[[@CR96]\]. Possibly, US1--US6 region would have its expression increased, as the whole region is generally related to immunomodulation, but was deleted in the production of TB40/E BAC on which Van Damme and colleagues based their study. As expected, most of the differentially expressed genes were related to immunomodulation, cell tropism (prominently UL74, US9, and US27) and adaptability to different cell types (as UL4 and UL5) \[[@CR96]\].

Batra et al. (BioProject PRJNA342503) proposed some advances on alternative therapeutic targets in 2016 \[[@CR97]\]. Cytoplasmic polyadenylation element binding protein 1 (CPEB1), responsible for cytoplasmic polyadenylation, was found to have a major role in infection-related cytopathology and post-transcriptional changes in different strains of HCMV (TB40/E and Towne) and in Herpes Simplex virus 2 in different tissue types \[[@CR97]\]. Decreased transcription levels of CPEB1 reduced viral RNA polyadenylation (shortening poly-A tails), alternative splicing and other RNA processing events, which leaded to a decrease of HCMV titers and shift in the transcription profile in comparison with a mock infection \[[@CR97]\].

Although pending for experimental validation, Zhang and colleagues (BioProject PRJNA340198) described the latent HCMV Towne infection cell transcriptome in THP-1 cells \[[@CR100]\], defining more than 2000 host differentially expressed genes, with approximately half of them with an upregulated expression profile. As expected, those differentially expressed genes were involved in pathways of apoptosis, inflammatory response and cell cycle progression \[[@CR100]\]. Interestingly, lncRNAs were differentially expressed with an ongoing HCMV latent infection \[[@CR100]\]. A year later, Cheng et al. (BioProject PRJNA389726) compared the expression of natural infection (healthy peripheral blood mononuclear cells latently infected with clinically uncharacterized HCMV) and experimental latency system in a transcriptome-wide study using positive strand SureSelect^XT^ target enrichment \[[@CR80]\]. The experimentally latent system used mutated TB40/E strains: ΔUL135--TB40/E (latent-like) and ΔUL138--TB40/E (strict-lytic). The SureSelect^XT^ enrichment represented a viral RNA increase between 74.35 and 81.2%, increasing viral read yield more than 6000 fold, without biasing the read distribution of the transcriptome \[[@CR80]\]. Strikingly, *wild-type* TB40/E and recombinant ΔUL135 were very similar in transcript composition and abundances \[[@CR80]\]. Alternatively, recombinant ΔUL138 infected cells harbored transcripts being antagonistically expressed in *wild-type* or ΔUL135 infected cells. Finally, the authors proposed a list of 30 core differentially "low to moderate levels" expressed genes in HCMV latent samples (ΔUL135 or clinical latent samples). Unfortunately, no lncRNA were analyzed \[[@CR80]\]. Shnyder and colleagues (BioProject PRJNA394123) used publicly available datasets and single-cell transcriptomics to define HCMV latency dynamics in infected cell populations. Interestingly, Shnyder et al. did not find any "clear restricted latency-associated expression program" \[[@CR102]\] or set of genes, that could clearly explain the transitions from lytic-to-latent or latent-to-lytic during infection. Furthermore, transcription levels in latent cells resembled more those of very late infection, with low to medium transcription rates. This overall change in transcriptional rate, as cause of transition between the two states, apparently conflicts with Cheng et al. 30 latency-associated candidate genes list \[[@CR80]\]. Further research is needed to understand the dynamics of latency in HCMV.

In 2017, Balázs and colleagues (BioProject PRJEB22072) reported the first HCMV transcriptome sequenced with long-read technology, the SMRT Bell™ Pacific Biosciences™ single molecule consensus platform. In this study, more than 291 novel transcript isoforms, 13 transcriptional starting sites (TSS), 22 transcriptional ending sites (TES) and 11 novel splicing events were characterized \[[@CR27]\]. Most isoforms displayed unique combinations of ORFs, modifying the length of the transcript. Most of the length differences between isoforms were caused by an N-terminal truncation, losing an additional ORF upstream of the main ORF. Moreover, 8 novel antisense transcripts to canonical ORFs (UL20, UL36, UL38, UL54, UL115, US1, US17, and US30), and a new partially antisense transcript (RS2) in the short repeat region \[[@CR27]\]. Balázs and colleagues also described transcript diversity in UL38 locus (i.e., hypothetical UL38A, longer form of UL38 with a putative non-canonical start codon), which has already been hypothesized to have a role in latency-to-replication transition in Cheng et al. \[[@CR80]\]. Oxford Nanopore Technologies™ direct RNA-sequencing could provide extra evidence, as it can allow for (i) sequencing RNA *directly* (no retrotranscription or amplification) and (ii) keeping *strand specificity*. Additionally, (iii) it permits sequence transcripts with very *different fragment sizes* (as opposed to SMRT Bell™ Pacific Biosciences™ approach in Balázs et al. where analyzed transcripts range between 1 and 2 kbp).

Conclusions and future challenges {#Sec7}
=================================

Almost 30 years have passed since the first full-length genome of HCMV was published \[[@CR7]\], and the amount of knowledge gathered with different NGS experiments has been invaluable to detangle the nature of this ubiquitous virus. Even with all information that has been collected and technologies developed, some challenges are yet to be addressed: (i) the centralization and integration of information, and (ii) the production of improved assemblies, notably in complex clonally heterogeneous samples.

HCMV genome-, expression- and translation information is scattered in literature, but by (i) improving protein orthology, (ii) collecting and unifying clinical data, and (iii) creating a dynamic and collaborative annotation environment, the scattered available information may be reconstructed and contextualized, providing a valuable broad picture of HCMV. Different annotation nomenclatures have existed for the past years \[[@CR7], [@CR104]\] and recently, a new protein orthology has been published \[[@CR8]\]. This new annotation, promoted by ViPR, is based on Domain-architecture Aware Inference of Orthologs (DAIO, Forester library) \[[@CR105]\], and already available phylogenetic classifications, offering a *manually high-quality curated* database of Strict Orthology Groups (SOG). Orthology groups may help to identify and classify new *Herpesviridae* genes and to understand the functional differences between the different orthologs.

Over the years, the number of sequenced clinical isolates has greatly increased, albeit clinical metadata linked to the viral isolates (i.e., gender, age, patient cohort, ethology of the disease or isolation year) has not. Most of this information remains unavailable or heavily scattered in the bibliography. Some resources, as ViPR \[[@CR8]\], provide centralized access to part of this metadata by automatically accessing GenBank records, although it remains incomplete as relies on non-standardized GenBank entries. An environment to deposit relevant clinical data with the corresponding viral information (i.e., isolate characteristics and genome) would provide high-quality information, helping to identify pathogenic determinants, as already has occurred for other viruses \[[@CR106]\]. Currently, most of HCMV genome and transcriptome are annotated by automatic or semi-automatic tools, based on pre-existing references (custom databases or annotation transfer tools, such as RATT \[[@CR107]\]). Unfortunately, not all annotations are updated with the current discoveries in HCMV expression and translation. A centralized and integrative RNA-seq platform would benefit the current state of annotation, as it would offer a constantly updated HCMV annotation contextualizing the available evidence from different experiments.

Finally, assemblies can be improved using different strategies, although *connectivity*, as previously discussed in this review, is one of its key aspects. Long-read technologies cannot only, *connect* scattered or unfinished regions of HCMV assemblies and characterize complete transcription events; but it can also provide a better understanding of structural and point variation in HCMV infections. Recently the term "ultra-long reads" (ULR), reads longer than 100 kbp, has been introduced \[[@CR108]\]. Theoretically, ULR could (partially) cover any of the unique regions (U~L~ or U~S~) of HCMV, or in exceptionally cases, bridging both unique regions, as reads longer than 1 Mbp have already been reported \[[@CR108]\]. Reads longer than 100 kbp may help to *unambiguously* connect distant variants from a clonally heterogeneous HCMV population.
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